Clinical Trial Update: Post-Autologous Transplant Maintenance With Isatuximab and Lenalidomide in Minimal Residual Disease Positive Multiple Myeloma [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating maintenance therapy with isatuximab and lenalidomide after autologous stem cell transplant in MRD-positive multiple myeloma; r…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Myeloma

Drugs mentioned

• Revlimid (lenalidomide)
• SARCLISA (isatuximab)

Snippet

Sponsor: University of Illinois at Chicago | Conditions: Multiple Myeloma | Phase 2 | Status: RECRUITING